Percorrer por autor "Lazo, Raul Edison"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Novel COVID-19 biomarkers identified through multi-omics data analysis: N-acetyl-4-O-acetylneuraminic acid, N-acetyl-L-alanine, N-acetyltriptophan, palmitoylcarnitine, and glycerol 1-myristatePublication . Cobre, Alexandre de Fátima; Alves, Alexessander Couto; Gotine, Ana Raquel; Domingues, Karime Zeraik; Lazo, Raul Edison; Ferreira, Luana Mota; Tonin, Fernanda; Pontarolo, RobertoThis study aims to apply machine learning models to identify new biomarkers associated with the early diagnosis and prognosis of SARS-CoV-2 infection. Plasma and serum samples from COVID-19 patients (mild, moderate, and severe), patients with other pneumonia (but with negative COVID-19 RT-PCR), and healthy volunteers (control) from hospitals in four different countries (China, Spain, France, and Italy) were analyzed by GC-MS, LC-MS, and NMR. Machine learning models (PCA and PLS-DA) were developed to predict the diagnosis and prognosis of COVID-19 and identify biomarkers associated with these outcomes. A total of 1410 patient samples were analyzed. The PLS-DA model presented a diagnostic and prognostic accuracy of around 95% of all analyzed data. A total of 23 biomarkers (e.g., spermidine, taurine, L-aspartic, L-glutamic, L-phenylalanine and xanthine, ornithine, and ribothimidine) have been identified as being associated with the diagnosis and prognosis of COVID-19. Additionally, we also identified for the first time five new biomarkers (N-Acetyl-4-O-acetylneuraminic acid, N-Acetyl-L-Alanine, N-Acetyltriptophan, palmitoylcarnitine, and glycerol 1-myristate) that are also associated with the severity and diagnosis of COVID-19. These five new biomarkers were elevated in severe COVID-19 patients compared to patients with mild disease or healthy volunteers. The PLS-DA model was able to predict the diagnosis and prognosis of COVID-19 around 95%. Additionally, our investigation pinpointed five novel potential biomarkers linked to the diagnosis and prognosis of COVID-19: N-Acetyl-4-O-acetylneuraminic acid, N-Acetyl-L-Alanine, N-Acetyltriptophan, palmitoylcarnitine, and glycerol 1-myristate. These biomarkers exhibited heightened levels in severe COVID-19 patients compared to those with mild COVID-19 or healthy volunteers.
- Old molecules, new hope: a scoping review and bibliometric analysis of drug repurposing for lung cancerPublication . Ragassi, Wellington Martins; Alves, Fernando Miguel; Lazo, Raul Edison; Tonin, Fernanda; Pontarolo, Roberto; Sari, Marcel Henrique; Ferreira, Luana MotaDrug repurposing has gained prominence in oncology by enabling the investigation of approved drugs for new therapeutic purposes. In lung cancer, this strategy may reduce the time and costs associated with drug development. This study aimed to map the landscape of in silico, in vitro, in vivo, and clinical research on drug repurposing for lung cancer, while identifying key molecular targets and research gaps. A systematic search was conducted in PubMed, Embase, and Web of Science, following Joanna Briggs Institute and PRISMA-ScR guidelines. Two reviewers independently selected and extracted the data. A total of 58 studies, published between 2010 and 2024, mainly from the United Kingdom (19%) and the United States (17%), were included. Most studies used in vitro models (53%), followed by in vivo (31%) and in silico (16%), with frequent combinations of methods. The most investigated drug classes were antibiotics (10%), antipsychotics (9%), antidiabetics (8%), anthelmintics (6%), and antihistamines (6%). Frequently studied drugs included niclosamide, metformin, atorvastatin, and doxazosin, targeting pathways such as PI3K/AKT/mTOR, apoptosis, and autophagy. Bibliometric analysis revealed increasing scientific output, with emphasis on combination therapies, cellular mechanisms, and technologies like molecular docking and nanosystems. These findings highlight the growing relevance of drug repurposing in lung cancer, especially in accelerating effective therapy discovery using approved compounds. Progress in this field depends on integrating diverse methodologies and fostering interdisciplinary collaboration. As a next step, rigorous clinical trials are essential to confirm the efficacy and safety of promising repurposed agents in oncology.